Ketamine offers rapid relief from severe depression and suicidal ideation, but its effects are often fleeting, creating a "fade" that leaves patients vulnerable. This Stanford study, published in the *American Journal of Psychiatry* (2026), tackles this challenge by exploring a novel pharmacological strategy: using low-dose buprenorphine to extend ketamine's benefits.

Researchers discovered that ketamine's magic might rely on the brain's mu-opioid receptor pathways, not just the glutamate system. Buprenorphine, a partial mu-opioid agonist, gently stimulates these pathways, acting like a "trellis" to support new neural connections formed by ketamine. This approach, tested on outpatients with severe depression and suicidal ideation, showed remarkable results. Patients receiving buprenorphine maintained a significant reduction in suicidal thoughts, while those on a placebo experienced a return of ideation.

Intriguingly, buprenorphine specifically targeted suicidal ideation without significantly impacting overall depression. This suggests that these conditions may operate on distinct neurobiological circuits, challenging the conventional view that suicidal ideation is simply an extreme symptom of depression. This study provides a potentially scalable and safe therapeutic option, offering a new key to turn off the switch for patients in desperate need.

Reference:

Tucciarone, J. M., Bandeira, I. D., Blasey, C., Kratter, I. H., Ehrie, J., Keller, J., Pankow, H., Chang, M., Hawkins, J., Evers, A. G., Bernert, R., DeBattista, C., Truong, H., Rodriguez, C. I., Heifets, B. D., & Schatzberg, A. F. (2026). Low-dose buprenorphine following ketamine treatment for suicidal ideation in major depressive disorder: A randomized, double-blind, placebo-controlled trial. *American Journal of Psychiatry*, *XX*(XX), 1–11. https://doi.org/10.1176/appi.ajp.20250840